| 33.99 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 90.08 | 1-year : | 105.22 |
| Resists | First : | 77.12 | Second : | 90.08 |
| Pivot price | 70.98 |
|||
| Supports | First : | 69.09 | Second : | 64.12 |
| MAs | MA(5) : | 70.04  |
MA(20) : | 71.94 |
| MA(100) : | 70.87 |
MA(250) : | 63.93 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 52.4 |
D(3) : | 49.5 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 78.58 | Low : | 50.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CNS ] has closed above bottom band by 48.3%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 72.45 - 72.81 | 72.81 - 73.09 |
| Low: | 69.15 - 69.64 | 69.64 - 70.03 |
| Close: | 70.12 - 70.84 | 70.84 - 71.44 |
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Sun, 21 Apr 2024
Why Constellation Pharmaceuticals (CNST) Might Surprise This Earnings Season? - Yahoo Movies Canada
Fri, 11 Jun 2021
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib - GlobeNewswire
Fri, 04 Jun 2021
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting - GlobeNewswire
Wed, 02 Jun 2021
MorphoSys acquires Constellation Pharma for $1.7B - Boston Business Journal - The Business Journals
Sun, 06 Dec 2020
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting - GlobeNewswire
Mon, 28 Sep 2020
Constellation Pharmaceuticals: Myelofibrosis Treatment Win Can Still Happen - We'll Know Soon (NASDAQ:CNST ... - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 47.9 (%) |
| Held by Institutions | 57 (%) |
| Shares Short | 1,510 (K) |
| Shares Short P.Month | 1,580 (K) |
| EPS | 2.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.76 |
| Profit Margin | 26.2 % |
| Operating Margin | 32.8 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -2.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.81 |
| EBITDA (p.s.) | 3.33 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 27.22 |
| PEG Ratio | 11.7 |
| Price to Book value | 9.12 |
| Price to Sales | 7.21 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|